Total
0
Shares
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald
Managing Director, Dr Rajen Manicka
Sourced: The Edge Markets
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Holista CollTech (HCT) has appointed Health Therapies as its exclusive distributor in the U.S. for its NatShield hand sanitiser
  • Health Therapies has exclusive access to the U.S. market for three years
  • It has committed to a minimum spend order of at least A$3 million per year.
  • A shipment of the first 5000 bottles of NatShield will be coming from Malaysia this week
  • Holista is now in discussions to introduce NatShield to more countries
  • The company is also developing online capabilities to better deliver NatShield
  • Holista shares are up a steady 16.3 per cent on the market today and are currently trading for 10 cents each

Holista CollTech (HCT) has appointed Health Therapies LLC as its exclusive distributor in the United States for NatShield.

Health Therapies has exclusive access to the U.S. market for three years and has committed to a minimum spend order of at least AUD$3 million per year.

The orders are for Holista's NatShield hand sanitisers, which contain Path-Away — a plant-based, active ingredient.

Path-Away is used in Holista's NatShield sanitising spray. It works by crippling a virus' cell walls, causing bacteria to group together and destroy themselves within seconds.

In mid-March, Holista began testing Path-Away's effectiveness against COVID-19. These tests are expected to be completed before the end of next month and results are expected within two to three weeks thereafter.

This testing will be completed in tandem with Global Infections Control Consultants LLC (GICC LLC).

A shipment of the first 5000 bottles of NatShield will be coming from Malaysia this week. Holista plans to bottle NatShield within the United States by next month.

"The appointment of a U.S. distributor is timely because of the escalating rate in the country. We are shipping sanitises out of Malaysia initially to meet the urgent needs," Holista CEO Dr Rajen Manicka said.

"Discussions have begun with U.S. bottlers who, part of the logistic supply chain of GICC LLC, can commit to up to one million bottles per month with capacity to scale further," he added.

Discussions are now underway on a number of further significant distribution and supply arrangements which, when finalised, will have an immediate effect of introducing NatShield to more countries.

Holista is also developing online capabilities to better deliver NatShield as needed.

With the global outbreak of COVID-19, Holista is also pleased to be in a stronger financial position after recently raising $4.33 million. This cash will help the company meet the global demand.

Holista shares are up a steady 16.3 per cent on the market in mid-morning trade and are trading for 10 cents each at 11:17 am AEDT.

HCT by the numbers
More From The Market Herald
Patrys (ASX:PAB) selects stable cell line for PAT-DX1 production

" AFT Pharmaceuticals (ASX:AFP) signs exclusive Maxigesic IV licensing agreement

AFT Pharmaceuticals has signed an exclusive Maxigesic IV licensing agreement for eight new European markets.
Althea Group (ASX:AGH) - CEO, Joshua Fegan - The Market Herald

" Althea Group’s (ASX:AGH) subsidiary gets A$137K order to make cannabis concentrates

Althea Group’s (AGH) subsidiary, Peak Processing Solutions, has received an C$134,000 (roughly A$137,216) purchase order from Peace Naturals Project.
Immutep (ASX:IMM) - CEO, Marc Voigt (left) - The Market Herald

" Immutep (ASX:IMM) expands TACTI-002 study

Immutep (IMM) has expanded Part B of its TACTI-002 phase two trial, following a recommendation from the data monitoring committee.
ImpediMed (ASX:IPD) - CEO, Rick Carreon - The Market Herald

" ImpediMed (ASX:IPD) completes 200,000 patient tests

ImpediMed  (IPD) says it has reached a milestone 200,000 patient tests for SOZO testing.